Adrenal Insufficiency, Critical Illness
Conditions
Keywords
Biological Response Modifiers, Endocrinology, Hormone Dysfunction, Hormones, Neuroendocrinology
Brief summary
Role fo oxidative stress in adrenal insufficiency has not been studied. The degree of oxidative stress and it's role in pediatric critical illness is unknown. Potential for significant alterations to many of thew body's regulatory pathways may result from severe oxidative stress. Further is needed to delineate what if any role oxidative stress may play
Detailed description
Adrenal insufficiency (AI) is common in critically ill children and adults. AI is a condition in which the adrenal glands, located above the kidneys, do not make enough hormones or our body is unable to use the hormones made. A hormone is a chemical that helps control different kinds of body functions. The hormones being studied can influence blood pressure and how fast the heart beats. Doctors want to know why children need extra hormones when they are critically ill. In our pediatric intensive care unit (PICU) we treat AI with a set of standard orders. By doing this, we have shown that AI is common in many types of sickness and that blood pressure improves when extra hormones are given. We also found that people's heart and blood pressure did not always match the level of a certain hormone, called cortisol, in their blood. Since cortisol levels alone don't always show AI, and children with normal hormone levels still benefit from steroids, doctors are looking for a better understanding of AI. Finding reasons that children develop AI may help doctors find other ways to improve AI. One promising focus of AI is the role of oxidative stress (OS). OS is a term used to describe a group of chemical reactions that involve oxygen. Emory's adult intensive care units have shown a significant increase in OS in critically ill patients. Normally our body's cortisol acts by binding to glucocorticoid (a class of hormone) receptors (GR) within cells. Many studies have shown that OS increases steroid resistance by changing the GR structure and function. Studies involving OS and GR problems have not been done with children. We aim to: 1. Find out how many sick children have OS in the PICU. 2. Find out the normal OS level of healthy children. 3. Decide if OS causes adrenal insufficiency.
Interventions
None listed
Sponsors
Children's Healthcare of Atlanta
Emory University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
1 Days to 18 Years
Healthy volunteers
No
Inclusion criteria
Critically Ill subjects: 1. All patients, birth-18 years, admitted to the pediatric intensive care unit that require blood to be drawn as part of medical management consistent with standard of care. 2. Admission to the PICU within the last 24 hours. 3. Subjects' legal guardian shall possess the ability to understand the purposes and risks of the study and provide an informed consent signature. Healthy control subjects: 1\. All healthy children, birth-18 years, who are having semi-elective magnetic resonance imaging (MRI) that require peripheral intravenous (PIV) catheters placed to provide sedation.
Exclusion criteria
Critically Ill subjects: 1. Have received steroids within the last 30 days. 2. Pre-existing/known neuroendocrine disorder, including but not limited to disorders of the hypothalamus, pituitary, adrenal, pancreas, or thyroid gland. 3. Have been treated at anytime with antipsychotic medication. 4. Human immunodeficiency virus (HIV) positive. 5. Patients who have received etomidate. 6. Patients weighing less than or equal to 6 kilograms. 7. Developmentally delayed. 8. Medical urgency preventing timely administration of the consenting process, or any condition that, in the opinion of the attending physician, would place the patient at undue risk by participating. 9. Other technical considerations that would prevent the timely acquisition of sufficient samples such as (but not limited to) hour of admission or absence of a study team member. 10. Parent or legal guardian (or patient when applicable) refuses to sign informed consent. Healthy control subjects: 1. Have received steroids within the last 30 days. 2. Have a pre-existing/known neuroendocrine disorder, including but not limited to disorders of the hypothalamus, pituitary, adrenal, pancreas, or thyroid gland. 3. Have been treated at anytime with antipsychotic medication. 4. Human immunodeficiency virus (HIV) positive. 5. Patients who have received etomidate. 6. Patients weighing less than or equal to 6 kilograms. 7. Developmentally delayed. 8. Medical urgency preventing timely administration of the consenting process, or any condition that, in the opinion of the attending physician, would place the patient at undue risk by participating. 9. Other technical considerations that would prevent the timely acquisition of sufficient samples such as (but not limited to) hour of admission or absence of a study team member. 10. Parent or legal guardian (or patient when applicable) refuses to sign informed consent.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Pediatric Logistic Organ Dysfunction Score in Critically Ill Children | 1 years | Pediatric Logistic Organ Dysfunction also known as the PELOD Score is a marker of severity of illness for Critically ill children. The PELOD includes six organ dysfunctions and 12 variables. To calculate the PELOD score, each organ dysfunction received points for the single variable associated with the most points. The minimum number that can be assigned to an organ is 0 and the maximum number of points for an organ is 20, and the maximum possible PELOD score is 71. Organ dysfunction is identified if the score for any organ system was more than 0. |
Secondary
| Measure | Time frame |
|---|---|
| Establish the OS Profile of Healthy Children to Act as Controls and Help Establish the Normal Pediatric Baseline. | 2 years |
| Analysis of Clinical Data to Determine Correlation of OS With AI and Evaluation of OS as a Potential Biomarker. | 2 years |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Critically Ill Patients Evaluation of Oxidative Stress, Glucocorticoid Receptor function, and Adrenal Insufficiency amongst critically ill pediatric patients. Serum, and when available endotracheal samples, will be obtained within 24 hours of admission and at 5 days provided patients are 1) still in the PICU and 2) blood draws and endotracheal aspirates are part of their standard of care. Endotracheal aspirates will be sent on day 14, 21, and 28 provided patients are intubated and require suctioning as part of their standard of care.
Cortrosyn: Subjects : a 1 microgram (mcg) dose of Cosyntropin via intravenous access. After 30 minutes, blood samples collected. | 60 |
| Healthy Controls Healthy controls will be evaluated and defined as those who do not have any chronic medical condition, are not on steroids (inhaled or oral), and have not received steroids or etomidate in the last month. Given the time and need for multiple lab draws low dose adrenocorticotropin (ACTH) testing will not be done in healthy patients, nor will tracheal aspirate samples be obtained. | 42 |
| Total | 102 |
Baseline characteristics
| Characteristic | Total | Critically Ill Patients | Healthy Controls |
|---|---|---|---|
| Age, Continuous | 9.7 years STANDARD_DEVIATION 5.3 | 10.9 years STANDARD_DEVIATION 5.6 | 8 years STANDARD_DEVIATION 4.5 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 5 Participants | 3 Participants | 2 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 97 Participants | 57 Participants | 40 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 54 Participants | 39 Participants | 15 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 9 Participants | 5 Participants | 4 Participants |
| Race (NIH/OMB) White | 39 Participants | 16 Participants | 23 Participants |
| Region of Enrollment United States | 102 participants | 60 participants | 42 participants |
| Sex: Female, Male Female | 47 Participants | 24 Participants | 23 Participants |
| Sex: Female, Male Male | 55 Participants | 36 Participants | 19 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — |
| other Total, other adverse events | 0 / 0 | 0 / 0 |
| serious Total, serious adverse events | 0 / 0 | 0 / 0 |
Outcome results
Primary
Pediatric Logistic Organ Dysfunction Score in Critically Ill Children
Pediatric Logistic Organ Dysfunction also known as the PELOD Score is a marker of severity of illness for Critically ill children. The PELOD includes six organ dysfunctions and 12 variables. To calculate the PELOD score, each organ dysfunction received points for the single variable associated with the most points. The minimum number that can be assigned to an organ is 0 and the maximum number of points for an organ is 20, and the maximum possible PELOD score is 71. Organ dysfunction is identified if the score for any organ system was more than 0.
Time frame: 1 years
Population: PELOD scores are not calculated for healthy controls. The score was developed to assess critically ill patients only.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Critically Ill Patients | Pediatric Logistic Organ Dysfunction Score in Critically Ill Children | 15.9 scores on a scale | Standard Deviation 13.7 |
Secondary
Analysis of Clinical Data to Determine Correlation of OS With AI and Evaluation of OS as a Potential Biomarker.
Time frame: 2 years
Secondary
Establish the OS Profile of Healthy Children to Act as Controls and Help Establish the Normal Pediatric Baseline.
Time frame: 2 years